Drugs  
comments_image Comments

Psychedelic Renaissance: LSD, Ecstasy and Magic Mushrooms Are Helping People Face Death, Cope with Trauma and Quit Booze and Smokes

Four decades after the counter-culture’s widespread recreational use of hallucinogens led to criminalization, there's new interest in their therapeutic potential.
 
 
Share
 
 
 
 

“The room instantly lit up in a blinding glare of white, white light. I was seized by an ecstasy such as I had never known,” wrote AA's co-founder, Bill Wilson, of his first spiritual experience.He was dropping acid as part of an informal study supervised by a doctor in the ‘50s, when LSD was legal and the power of psychedelic-assisted therapy was heralded as potentially transformative.

So began  a lifelong interest in altered states of consciousness that included extensive experiments with LSD. Wilson claimed that his initial experiences were crucial to his recovery and his belief in his mission to create a community of alcoholics helping one another. He was so enthusiastic that he contemplated  advising other AA members to take acid, especially those incapable of feeling “a power greater than ourselves.” Still, he acknowledged the limits of its possible benefits: “I don't believe [LSD] has any miraculous property of transforming…sick people into healthy ones overnight,” he wrote to a fellow participant in the study. "[But] it can set up a shining goal on the positive side [and] create a large incentive [to recovery.]” 

The AA fellowship disagreed. The idea of treating those who cannot control their substance use with another substance seemed, then as now, heretical. The link between spirituality and sobriety, however, remains a mainstay of modern recovery.

Today, some four decades after the counter-culture’s widespread recreational use of hallucinogens led to criminalization of the substances, there's a resurgence of interest in their therapeutic potential for mental illness and addiction. A dozen or more studies of LSD, psilocybin (the active ingredient in magic mushrooms) and MDMA (ecstasy) are ongoing in the US, Britain, Israel and Switzerland; a handful of others have recently concluded. Most of the patients involved in these studies are in dire straits: vets with PTSD, the terminally ill who have a terror of death, people with treatment-resistant depression and alcoholics.

The results are consistently positive. Indeed, the  PTSD and cancer studies have garnered big headlines recently for their exceptionally beneficial outcomes. But these are tiny pilot studies—and because the drugs are still illegal and mired in controversy and stigma, research is likely to remain stalled.

Advances in neuroscience, coupled with the new model of mental illness and addiction as brain diseases, are largely responsible for rekindling this research. Neurons and their transmitters, receptors, pathways and the like are increasingly viewed as the source of the “self” and perception, cognition, emotion and other functions. Psychedelics have a uniquely powerful, even explosive, effect on both your neurochemistry and your “self.” But the trip itself typically only lasts for about 12 hours. Whether these "mystical" effects deliver enduring benefits is the question researchers seek to answer, for only then could these substances become “medicines.”

Rick Doblin believes the answer is yes. He's the founder and president of the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS), which funds pilot studies and advocates for these drugs' use in legal medical settings. “Addiction involves past material, a lot of denial and running away. Psychedelics bring material to the surface in ways where people need to surrender to them; it’s hard to hide from yourself under [them],” says Dobin. “The other part is more positive. People often have a spiritual sense of connection that they can later draw strength from.”

Psychedelic-based treatment can cause elevation in mood, openness and changes in values—which, for people with substance use disorders, can cause a reduction in craving, increase in motivation and, ultimately, a reduction in use, says Michael Bogenschutz, MD, a psychiatry professor at the University of New Mexico. “[But] the tricky thing is developing a neurobiological theory. We know a fair amount about the  acute effects of psilocybin and drugs like it on the brain, and we’re learning something about the functional effects with  fMRI,” he says. “So how do you get from those acute effects to a  longer-lasting effect on behavior?”

 
See more stories tagged with: